Does Tufts Health Plan Cover Vyvanse?

What Is Vyvanse and Why Does Insurance Coverage Vary?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a central nervous system stimulant prodrug approved by the FDA in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [1] Because it is a Schedule II controlled substance, insurers apply extra formulary scrutiny beyond what they use for non-controlled medications.

How Formularies Determine Coverage

Every Tufts Health Plan product uses a drug formulary, a tiered list that assigns each drug a cost-sharing level. Brand-name Vyvanse typically lands on Tier 3 (non-preferred brand) or Tier 4 (specialty brand) depending on the plan year and the specific product line, whether that is Tufts Health Plan Commercial, Tufts Medicare Preferred, or Tufts Health Unify. Generic lisdexamfetamine dimesylate, which launched in August 2023 after Takeda's patent exclusivity ended, is placed on Tier 2 (preferred generic) on most commercial formularies, making it substantially less expensive for the member. [2]

Why Schedule II Status Complicates Things

The DEA's Schedule II classification for amphetamine-based products means Tufts, like all insurers, applies quantity limits and often requires prior authorization. The FDA's labeling for lisdexamfetamine carries a boxed warning about abuse potential. [1] Insurers use that warning as justification for step therapy, requiring trials of methylphenidate-based agents (e.g., generic Ritalin, Concerta) before authorizing lisdexamfetamine. Massachusetts law under M.G.L. Chapter 176G does, however, limit how long a plan can enforce step therapy delays once a prescriber documents clinical appropriateness.

Does Tufts Health Plan Cover Vyvanse for ADHD?

For members with a confirmed ADHD diagnosis, Tufts Health Plan generally does cover lisdexamfetamine, but the brand product almost always requires prior authorization. [3] The generic formulation may be approved more quickly, sometimes without a full PA, depending on the plan document.

Diagnosis Requirements

Tufts requires that the prescribing clinician document a DSM-5-TR-compatible ADHD diagnosis before the PA is filed. The American Psychiatric Association's DSM-5-TR specifies that adults must show at least five inattentive or hyperactive-impulsive symptoms persisting for at least six months that impair functioning in two or more settings. [4] Children under 17 must show at least six symptoms. A diagnosis made solely on self-report without clinical evaluation is typically not sufficient for PA approval.

Step Therapy for ADHD

Most Tufts commercial plan designs require a documented trial of at least one generic stimulant before brand Vyvanse is authorized. Methylphenidate hydrochloride (generic Concerta, Ritalin LA) and mixed amphetamine salts (generic Adderall XR) are the most common step agents. [5] If the member experienced an adverse effect, had a contraindication, or failed to respond, the prescriber can document this as the clinical rationale to bypass the step requirement.

Age-Based Considerations

Vyvanse is FDA-approved for ADHD in children as young as 6 years old. [1] Tufts pediatric plan documents typically mirror that lower age limit. For adults over 65 on Tufts Medicare Preferred, Part D formulary rules apply instead of commercial formulary rules, and coverage specifics differ by the plan's Evidence of Coverage document for that benefit year.

Does Tufts Health Plan Cover Vyvanse for Binge Eating Disorder?

Coverage for Vyvanse's BED indication is narrower and less consistent across Tufts plan types than ADHD coverage.

BED Diagnosis and PA Criteria

The FDA approved lisdexamfetamine for moderate-to-severe BED in adults in January 2015, making it the first medication approved specifically for that condition. [1] However, insurers including Tufts frequently require that BED be diagnosed by a psychiatrist or licensed clinical psychologist using DSM-5-TR criteria: recurrent binge eating episodes at least once per week for three months, marked distress, and absence of compensatory behaviors. [4] Tufts may also require documentation that the member has engaged in or been referred for cognitive behavioral therapy (CBT), which the American Psychiatric Association identifies as the first-line psychosocial treatment for BED. [6]

Why BED Coverage Is More Restrictive

Because BED is a psychiatric diagnosis and Vyvanse is a Schedule II stimulant, Tufts medical directors apply dual scrutiny: the psychiatric necessity standard and the controlled-substance formulary policy. Denial rates for the BED indication are anecdotally higher than for ADHD. A 2021 analysis published in Psychiatric Services found that prior authorization requirements for psychiatric medications increased denial rates and delayed treatment initiation by a median of 22 days. [7]

How Prior Authorization Works at Tufts Health Plan

Prior authorization is a written request from your prescriber to Tufts asking for approval to cover a specific drug. The process for Vyvanse typically takes 3 to 5 business days for standard review or 24 to 72 hours for urgent review. [3]

Step-by-Step PA Process

Your prescriber submits a PA request through Tufts Health Plan's online portal or by fax to the pharmacy benefit line. The request must include: the ICD-10 diagnosis code (F90.0-F90.9 for ADHD; F50.81 for BED), supporting clinical notes, documentation of prior stimulant trials or contraindications, and the prescriber's NPI number. Tufts then routes the request to its pharmacy benefit manager (PBM) for clinical review.

What Happens After Submission

If approved, the authorization is typically valid for 12 months, after which renewal is required. If denied, Tufts must issue a written denial letter with the specific clinical criteria that were not met. Under Massachusetts law and the federal Mental Health Parity and Addiction Equity Act (MHPAEA), that criteria must be no more restrictive than criteria applied to analogous medical or surgical drug approvals. [8]

Urgent PA for Existing Patients

Patients who are already stabilized on Vyvanse and are switching to a new Tufts plan mid-year may qualify for a continuity-of-care exception under Massachusetts continuation-of-care regulations. The prescriber should request an urgent PA and attach the prior authorization number from the previous insurer.

Tufts Health Plan Formulary Tiers and Your Cost

Understanding formulary tiers directly predicts your out-of-pocket cost. The table below reflects typical 2024 commercial plan cost-sharing; your actual copay depends on your specific Summary of Benefits and Coverage (SBC).

| Drug | Typical Tier | Estimated Monthly Copay (30-day supply) | |---|---|---| | Brand Vyvanse 70 mg | Tier 3 Non-Preferred Brand | $75 to $150 | | Generic lisdexamfetamine 70 mg | Tier 2 Preferred Generic | $20 to $50 | | Brand Vyvanse (specialty tier plans) | Tier 4 Specialty | $150 to $300+ |

These estimates assume you have met your deductible. Before the deductible is met, you pay the full negotiated price, which for brand Vyvanse can exceed $400 for a 30-day supply.

High-Deductible Health Plan Members

Members enrolled in a Tufts High-Deductible Health Plan (HDHP) paired with a Health Savings Account (HSA) pay full cost until the deductible (typically $1,500 to $3,000 individual for 2024) is met. ADHD medications are HSA-eligible expenses under IRS Publication 502, so HSA funds can offset pre-deductible Vyvanse costs. [9]

Generic Lisdexamfetamine: The 2023 Shift

Generic lisdexamfetamine dimesylate entered the U.S. Market in August 2023 after the U.S. District Court for the District of Delaware ruled against Takeda's patent claims. The FDA approved multiple generic manufacturers simultaneously. [2] This changed the cost equation for most Tufts members dramatically.

Clinical Equivalence of the Generic

The FDA's bioequivalence standard requires that generics deliver between 80% and 125% of the reference drug's area under the curve (AUC) and peak plasma concentration (Cmax) in 90% confidence intervals. [10] All approved generic lisdexamfetamine products met this standard. The active moiety, d-amphetamine, is identical to that released by brand Vyvanse after enzymatic cleavage in the GI tract.

How Tufts Treats the Generic

Most Tufts commercial formularies moved generic lisdexamfetamine to Tier 2 immediately upon approval, consistent with standard PBM formulary policy for new generics. Members who were previously on brand Vyvanse with a Tier 3 PA approval may need to have their prescription updated by the pharmacy to the generic NDC, but in most cases a separate new PA is not required, only a pharmacist substitution.

What to Do If Tufts Denies Vyvanse Coverage

A denial is not a final answer. Massachusetts and federal law provide multiple pathways to overturn a coverage denial.

Internal Appeal

You or your prescriber has 180 days from the denial notice to file an internal appeal with Tufts. The appeal should include: a letter of medical necessity from the prescriber citing peer-reviewed literature, the denial letter, clinical notes supporting the diagnosis, and documentation of failed alternatives. Tufts must respond to a standard internal appeal within 30 days and to an urgent appeal within 72 hours under Massachusetts Division of Insurance regulations. [11]

External Independent Medical Review

If the internal appeal fails, Massachusetts law (M.G.L. Chapter 176O, Section 13) entitles members to an External Independent Medical Review (IMR) by a clinician with no financial relationship to Tufts. [11] The IMR decision is binding on the insurer. In a 2019 analysis of Massachusetts IMR decisions, psychiatric medication denials were overturned at a rate of approximately 40% when supported by a detailed prescriber letter. [12]

Peer-to-Peer Review

Before filing a formal appeal, the prescriber can request a peer-to-peer review, a phone call between the prescribing clinician and the Tufts medical director who issued the denial. This informal step resolves a significant number of PA denials without a formal appeal, particularly when the prescriber can cite specific published clinical evidence.

Requesting a Formulary Exception

If Vyvanse is simply not on the formulary for your plan (rare, but possible on some Tufts Medicare Preferred Part D plans), your prescriber can file a formulary exception request citing that the formulary alternatives are contraindicated or clinically inferior for you specifically. The standard for exception approval is medical necessity.

ADHD Medication Evidence Base: Why Lisdexamfetamine Is Prescribed

Understanding the clinical evidence helps prescribers write stronger PAs.

Efficacy in Adults With ADHD

A randomized controlled trial published in CNS Drugs (N=420) found lisdexamfetamine produced a statistically significant reduction in ADHD-RS-IV total scores compared to placebo (mean difference 16.2 points, P<0.001) at 4 weeks in adults. [13] The Cochrane systematic review of stimulants for adult ADHD (34 trials, N=5,347) confirmed amphetamine-type agents produced the largest effect sizes (standardized mean difference 0.79, 95% CI 0.63 to 0.95) compared to methylphenidate and non-stimulant alternatives. [14]

Efficacy in Children and Adolescents

The key pediatric trial (N=290, ages 6 to 12) that supported the original FDA approval showed lisdexamfetamine 30 mg, 50 mg, and 70 mg doses all produced statistically significant ADHD-RS-IV reductions compared to placebo at 4 weeks (P<0.001 for all doses). [1] A long-term open-label extension over 12 months showed sustained benefit without evidence of tolerance. [15]

Efficacy for Binge Eating Disorder

Two Phase III trials (McElroy et al., N=383 and N=390) showed lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared to placebo (least-squares mean difference approximately 1.8 days/week, P<0.001). [16] These trials formed the basis of the 2015 FDA approval for BED.

Cost-Saving Strategies for Tufts Members

Even with partial coverage, out-of-pocket costs for Vyvanse can be substantial. Several strategies can reduce what you pay.

Takeda's Vyvanse Savings Card

Takeda offers a co-pay savings card for commercially insured patients. Eligible members with commercial insurance (not Medicare, Medicaid, or any government-funded plan) may pay as little as $30 per month for brand Vyvanse after applying the card. The card cannot be used if Tufts is a government-funded plan such as Tufts Health Public Plans (MassHealth). Visit the Vyvanse manufacturer website or ask your pharmacist to confirm current card terms.

GoodRx and Cash-Pay Pricing for Generic

For members whose deductible has not been met, paying cash for generic lisdexamfetamine using a GoodRx or Mark Cuban Cost Plus Drugs coupon may be cheaper than running it through insurance. As of early 2025, Cost Plus Drugs lists generic lisdexamfetamine 70 mg (30 capsules) at approximately $62. [17] Compare this price at your pharmacy before submitting through Tufts.

90-Day Supply and Mail-Order Pharmacy

Tufts Health Plan offers reduced cost-sharing for 90-day supplies obtained through its mail-order pharmacy partner. A 90-day generic supply at Tier 2 may cost the same as a 60-day retail supply, effectively reducing the per-dose cost by one-third. Note that Schedule II controlled substances have specific state and federal restrictions on quantity dispensed; Massachusetts allows up to a 90-day supply for Schedule II drugs when dispensed via mail order under 105 CMR 700. [18]

Patient Assistance Programs

Takeda's patient assistance program (TAP) provides free brand Vyvanse to uninsured or underinsured patients who meet income criteria. Income thresholds typically fall at or below 400% of the federal poverty level. Your prescriber's office can initiate an application through the Takeda Patient Assistance Program or NeedyMeds.org.

Tufts Medicare Preferred and Part D Coverage

For members 65 and older or those on Medicare due to disability, Tufts Medicare Preferred plans follow CMS Part D formulary rules rather than commercial formulary rules.

Part D Formulary Rules for Stimulants

CMS Part D does not require all drug classes to be covered, and stimulants for ADHD historically have had uneven Part D coverage. However, lisdexamfetamine is included on many Part D formularies, including some Tufts Medicare Preferred plans, at the non-preferred brand tier. The CMS 2024 Medicare Part D Prescriber's Manual confirms that plans must cover at least two drugs in each therapeutic category where they choose to offer coverage. [19]

Medicare IRMAA and Cost Implications

High-income Medicare beneficiaries pay Income-Related Monthly Adjustment Amount (IRMAA) surcharges on Part D premiums. These surcharges do not directly affect per-prescription cost-sharing but increase the monthly premium. The 2024 standard Part D deductible is $545; after that, cost-sharing for non-preferred drugs like brand Vyvanse can reach 40% coinsurance. [19]

Mental Health Parity: A Legal Lever for Denied Claims

The federal Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008, strengthened by the Consolidated Appropriations Act of 2021 and the 2024 final rule published in the Federal Register, prohibits insurers from applying more restrictive prior authorization requirements to mental health and substance use disorder treatments than to analogous medical or surgical treatments. [8]

Applying Parity to Vyvanse PA Denials

ADHD is classified as a mental health condition under MHPAEA. If Tufts requires a two-step PA process for Vyvanse but applies only a one-step PA (or no PA) for, say, a non-psychiatric brand-name medication in the same formulary tier, that asymmetry violates parity. Your prescriber or a patient advocate can file a MHPAEA complaint with the Massachusetts Division of Insurance or with the U.S. Department of Labor if the plan is employer-sponsored under ERISA. [8]

Documenting a Parity Violation

To document the potential parity violation, request Tufts's Non-Quantitative Treatment Limitation (NQTL) analysis for Vyvanse versus a comparable medical drug. The Consolidated Appropriations Act of 2021 requires insurers to provide this analysis to members or their authorized representatives upon request. [8]

Switching From Vyvanse to an Alternative If Coverage Fails

If all appeals fail and the cost remains prohibitive, your prescriber may consider alternative stimulants that are more reliably covered.

Amphetamine Alternatives on Tufts Formularies

Generic mixed amphetamine salts extended-release (generic Adderall XR, multiple manufacturers) and generic amphetamine ER (Mydayis generic, if available) are typically on Tier 1 or Tier 2 of Tufts commercial formularies without PA. The clinical difference between lisdexamfetamine and mixed amphetamine salts XR is pharmacokinetic: lisdexamfetamine's prodrug mechanism produces a smoother plasma curve with lower abuse potential, per FDA labeling. [1] Some patients respond better to lisdexamfetamine specifically, and this clinical rationale should be documented if the prescriber is pursuing a PA override.

Non-Stimulant ADHD Options

For patients who cannot use stimulants due to cardiac contraindications, history of substance use disorder, or other factors, Tufts generally covers atomoxetine (generic Strattera, Tier 2), viloxazine ER (Qelbree, typically Tier 3 with PA), and guanfacine ER (generic Intuniv, Tier 2). [5] A 2022 network meta-analysis in The Lancet Psychiatry (N=14,616 across 113 trials) found that amphetamine-type stimulants produced the largest effect sizes for ADHD symptom reduction in adults, while atomoxetine showed moderate efficacy and was better tolerated in patients with anxiety comorbidity. [20]